Daniel Van Plew
2020
Compensation breakdown
Non-Equity Incentive Plan | $938,872 |
---|---|
Option Awards | $3,459,499 |
Salary | $825,577 |
Stock Awards | $3,409,560 |
Other | $20,945 |
Total | $8,654,453 |
Van Plew received $3.5M in option awards, accounting for 40% of the total pay in 2020.
Van Plew also received $938.9K in non-equity incentive plan, $825.6K in salary, $3.4M in stock awards and $20.9K in other compensation.
Rankings
In 2020, Daniel Van Plew's compensation ranked 1,047th out of 13,090 executives tracked by ExecPay. In other words, Van Plew earned more than 92.0% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 1,047 out of 13,090 | 92nd |
Division Manufacturing | 369 out of 5,624 | 93rd |
Major group Chemicals And Allied Products | 127 out of 2,257 | 94th |
Industry group Drugs | 111 out of 1,957 | 94th |
Industry Pharmaceutical Preparations | 81 out of 1,462 | 95th |
Van Plew's colleagues
We found four more compensation records of executives who worked with Daniel Van Plew at Regeneron Pharmaceuticals in 2020.
2020
Leonard Schleifer
Regeneron Pharmaceuticals
Chief Executive Officer
2020
George Yancopoulos
Regeneron Pharmaceuticals
Chief Scientific Officer
2020
Andrew Murphy
Regeneron Pharmaceuticals
Executive Vice President, Research
2020
Robert Landry
Regeneron Pharmaceuticals
Chief Financial Officer
News
April 21, 2022
April 23, 2021
April 24, 2020
April 26, 2019